Feb. 3 at 3:50 PM
🚨
$INBS: Disrupting the
$19B Drug Testing Market
🔹 The Catalyst: Clinical studies are officially underway (as of Jan 28) for FDA clearance—the final hurdle to enter the massive U.S. market.
🔹 The Tech: World’s first fingerprint sweat drug test. Results in <10 mins. No needles, no bathrooms, no biohazards.
🔹 The Money: Just secured
$10M in fresh capital and a new manufacturing deal set to boost profit margins by 20%.
🔹 Proven Success: Already sold 500,000+ tests globally. The U.S. launch is the next major leg of growth.
Why
$INBS is a top watch:
🔸 Faster & Cheaper: Replaces slow, invasive urine/saliva tests for workplaces and law enforcement.
🔸 Razor-Blade Model: Each portable reader sold creates a lifetime of recurring revenue from test cartridges.
🔸 Huge Upside: Positioned to dominate safety-critical industries (Construction, Transport, Mining).
Communicated Disclaimer - https://chartingdaily.com/next-gen-diagnostics
Other stocks moving up today:
$TIRX $GXAI $PIII